Burden of EPS in Commercial Patients With Schizophrenia Initiating Atypical Antipsychotics
This study investigated the 1-year incidence of extrapyramidal symptoms (EPS), as well as the incremental economic burden, in patients with schizophrenia initiating atypical antipsychotics.
Key Considerations for Choosing the Right SMA Treatment
Experts Spotlight Lasting Innovations From the COVID-19 Pandemic
AJMC® in the Press, April 4, 2025
5 Things to Know About Infertility